Journal article
A potent Nrf2 activator, dh404, bolsters antioxidant capacity in glial cells and attenuates ischaemic retinopathy
D Deliyanti, JY Lee, S Petratos, CJ Meyer, KW Ward, JL Wilkinson-Berka, JB de Haan
Clinical Science | PORTLAND PRESS LTD | Published : 2016
DOI: 10.1042/CS20160068
Abstract
An imbalance in oxidative stress and antioxidant defense mechanisms contributes to the development of ischaemic retinopathies such as diabetic retinopathy and retinopathy of prematurity (ROP). Currently, the therapeutic utility of targeting key transcription factors to restore this imbalance remains to be determined. We postulated that dh404, an activator of nuclear factor erythroid-2 related factor 2 (Nrf2), the master regulator of oxidative stress responses, would attenuate retinal vasculopathy by mechanisms involving protection against oxidative stress-mediated damage to glia. Oxygen-induced retinopathy (OIR) was induced in neonatal C57BL/6J mice by exposure to hyperoxia (phase I) followe..
View full abstractGrants
Awarded by Trish Multiple Sclerosis Research Foundation
Awarded by National Multiple Sclerosis Society
Funding Acknowledgements
This work was supported by the Multiple Sclerosis Research Australia Postgraduate Scholarship (to J.Y.L.); the Trish Multiple Sclerosis Research Foundation [grant number #12-060 (to J.Y.L.)]; the National Multiple Sclerosis Society Project [grant number RG4398A1/1 (to S.P.)]; the Reata Pharmaceuticals, Inc. (to J.B.dH.); and the Victorian Government's Operational Infrastructure Support Program.